Pharmaceuticals, Biotechnology and Life Sciences
Oasmia Pharmaceutical has named Anette Sjödin as Executive Vice President as of June 1, 2019 and Maria Nilsson Hagberg as Head of Regulatory Affairs as of April 18, 2019.
Zealand Pharma has doesd its first patient in Phase 3 trial with dasiglucagon for the treatment of congenital hyperinsulinism, the company said Wednesday.
Bexion’s Phase I First-In-Human Trial using BXQ-350 for the treatment of cancer has exceeded expectations in screening and enrollment at their 4 trial sites.
FDA has granted Priority Review for Eli Lilly’s sBLA for Emgality (galcanezumab-gnlm) injection for the preventive treatment of episodic cluster headache in adults, the company said Tuesday in a press release.
Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Telmisartan and Hydrochlorothiazide Tablets .
Novartis has had Cosentyx compared against Janssen’s IL-23 Stelara, and it showed superior improvements for psoriasis patients, it said in a statement Tuesday, noting that it was processed and transmitted by West Corporation.
BioPharmX Corporation has enrolled patients for its Phase 2b testing BPX-04, a new drug limited by U.S. law to investigational use, topical gel formulation of fully solubilized minocycline for the treatment of papulopustular rosacea.
Shield Therapeutics got positive results from the AEGIS-H2H clinical trial which compared Feraccru (ferric maltol) to Ferinject (ferric carboxymaltose (FCM)), as Feraccru has demonstrated it is non-inferior to IV iron therapy in treating iron deficiency anaemia.
Biogen said Monday it will buy Nightstar Therapeutics, a clinical-stage gene therapy company based in London, United Kingdom, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders.
Verona Pharma is aiming to start second part of Phase 2 trial to test ensifentrine DPI formulation in patients with moderate-to-severe COPD over one week of twice-daily treatment, it said after announcing positive data from part one of the trial.